Inactive Instrument

Xbrane Biopharma AB Stock Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Xbrane Biopharma AB
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 344M 31.87M 43.57M Sales 2025 * 680M 63.1M 86.26M Capitalization 309M 28.66M 39.18M
Net income 2024 * -186M -17.25M -23.59M Net income 2025 * 104M 9.65M 13.19M EV / Sales 2024 * 0.82 x
Net cash position 2024 * 28.17M 2.61M 3.57M Net Debt 2025 * 116M 10.74M 14.68M EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
-1.5 x
P/E ratio 2025 *
4.22 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.26%
More Fundamentals * Assessed data

Latest transcript on Xbrane Biopharma AB

Managers TitleAgeSince
Chief Executive Officer 44 14-12-31
Director of Finance/CFO 63 21-01-10
Chief Tech/Sci/R&D Officer 42 17-10-08
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 70 14-12-31
Director/Board Member 53 19-12-31
More insiders
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW